Agios to Participate in March Investor Conferences

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the company is scheduled to present at the following March investor conferences:

• Cowen 42nd Annual Virtual Healthcare Conference on Monday, March 7, 2022, at 9:10 a.m. ET; and
• Oppenheimer 32nd Annual Virtual Healthcare Conference on Wednesday, March 16, 2021 at 1:20 p.m. ET.

Live webcasts of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.

About AgiosAgios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for genetically defined diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with active and planned programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company’s website at www.agios.com.

Contacts

Investors:Holly Manning, 617-844-6630Senior Director, Investor Relations[email protected]

Media:Jessica Rennekamp, 857-209-3286Director, Corporate Communications[email protected] 

Source: Agios Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• The American Kidney Fund and IgA Nephropathy Foundation Create New IgA Nephropathy Patient Guidelines
• StarRez's 2026 State of the Student Housing Industry Report Finds Student Housing Shifts Toward a More Strategic, Connected Model
• 70% of U.S. Workers Can't See the Data Behind Their Company's Strategy, New 80/20 Institute Study Finds